Flagship Product
Undisclosed
Pre-clinical/DiscoveryActive
Key Facts
About CirculaTech
CirculaTech is an emerging player in the diagnostics and digital health sector, operating in stealth mode with its core technology and product pipeline still under wraps. The company's financial backing is indicated through Phase I SBIR and STTR grants, suggesting a focus on innovative, high-risk research with U.S. government support. With minimal public information, the company's strategy seems centered on achieving a key development milestone for its flagship product before seeking broader partnerships or funding. Its success will hinge on the clinical validity and market differentiation of its yet-to-be-revealed platform.
View full company profileOther Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |